Biohit Oyj — Share Issue/Capital Change 2026

Apr 1, 2026

Biohit Plc B-shares Subscribed with Stock Options I 2021D

Biohit Plc B-shares Subscribed with Stock Options I 2021D

Biohit Plc Stock Exchange Release 1.4.2026 at 2:00 p.m. (EEST)

A total of 8,000 new Biohit Plc’s B-shares have been subscribed for with stock options I 2021D by 12 March 2026. These shares have been entered into the Trade Register on 1 April, 2026, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. The new shares will be traded on Nasdaq Helsinki Ltd’s main list together with the existing B-shares on or about 2 April, 2026.

The share subscription price was EUR 1.00 per share respectively. The entire subscription price of EUR 8,000.00 will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value.

After the subscriptions the number of all Biohit Plc's shares will rise to 15,205,593 shares and B-shares will rise to 12,230,093 shares.

The share subscription period with stock options I 2021D began on March 1, 2026 and ends on March 1, 2028. The option scheme is based on the Biohit Plc board resolution of December 7, 2021 and the Annual General Meeting authorization of September 16, 2020.

The terms and conditions of the option schemes with additional information are available on Biohit Plc website at www.biohithealthcare.com.

Additional information: 

Jussi Hahtela, CEO, Biohit Oyj, tel. +358 50 383 5948

investor.relations@biohit.fi

www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com